JP2021512161A5 - - Google Patents

Info

Publication number
JP2021512161A5
JP2021512161A5 JP2020562086A JP2020562086A JP2021512161A5 JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5 JP 2020562086 A JP2020562086 A JP 2020562086A JP 2020562086 A JP2020562086 A JP 2020562086A JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5
Authority
JP
Japan
Prior art keywords
hydrogen
pharmaceutically acceptable
solvate
compound according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020562086A
Other languages
English (en)
Japanese (ja)
Other versions
JP7337395B2 (ja
JP2021512161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015547 external-priority patent/WO2019148161A1/en
Publication of JP2021512161A publication Critical patent/JP2021512161A/ja
Publication of JP2021512161A5 publication Critical patent/JP2021512161A5/ja
Application granted granted Critical
Publication of JP7337395B2 publication Critical patent/JP7337395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020562086A 2018-01-29 2019-01-29 Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用 Active JP7337395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2021512161A JP2021512161A (ja) 2021-05-13
JP2021512161A5 true JP2021512161A5 (cg-RX-API-DMAC10.html) 2022-01-17
JP7337395B2 JP7337395B2 (ja) 2023-09-04

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562086A Active JP7337395B2 (ja) 2018-01-29 2019-01-29 Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用

Country Status (15)

Country Link
US (1) US11352341B2 (cg-RX-API-DMAC10.html)
EP (1) EP3746072B1 (cg-RX-API-DMAC10.html)
JP (1) JP7337395B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200115583A (cg-RX-API-DMAC10.html)
CN (1) CN111989099A (cg-RX-API-DMAC10.html)
AU (1) AU2019211491B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020015405A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088381A1 (cg-RX-API-DMAC10.html)
EA (1) EA202091450A1 (cg-RX-API-DMAC10.html)
IL (1) IL275948A (cg-RX-API-DMAC10.html)
MX (1) MX2020007959A (cg-RX-API-DMAC10.html)
PH (1) PH12020551155A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202006748RA (cg-RX-API-DMAC10.html)
TW (1) TW201940166A (cg-RX-API-DMAC10.html)
WO (1) WO2019148161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
AU2019289176B2 (en) * 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
TW202521536A (zh) * 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk抑制劑
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2,4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Similar Documents

Publication Publication Date Title
CN115803326A (zh) Egfr抑制剂及其制备方法与在药学上的应用
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2023525656A (ja) Egfr阻害剤、その調製方法及びその使用
JP2014513110A5 (cg-RX-API-DMAC10.html)
JP2020500862A5 (cg-RX-API-DMAC10.html)
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2018517686A5 (cg-RX-API-DMAC10.html)
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
JP2018536634A5 (cg-RX-API-DMAC10.html)
JP2018516917A5 (cg-RX-API-DMAC10.html)
JP2021512087A5 (cg-RX-API-DMAC10.html)
CN109803972A (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
JP2020504738A5 (cg-RX-API-DMAC10.html)
CN102395576A (zh) 调控jak激酶的喹唑啉衍生物和其使用方法
CN103124729A (zh) 作为Axl抑制剂的药物活性化合物
JP2022071077A5 (cg-RX-API-DMAC10.html)
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2019518079A5 (cg-RX-API-DMAC10.html)
JP2022553954A5 (cg-RX-API-DMAC10.html)
JP2005525322A5 (cg-RX-API-DMAC10.html)
JP5860895B2 (ja) 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2002544195A (ja) Mek酵素の阻害薬としてのキノリン誘導体
JP2023509944A5 (cg-RX-API-DMAC10.html)
CN104557939A (zh) 吡咯并吡嗪化合物的盐酸盐及其应用